康方生物在一项临床三期试验中赢了百济神州的PD-1抗体联合疗法

每日经济新闻2025-04-23

康方生物（9926.HK，股价92.3港元，市值828.46亿港元）双抗药物依沃西又一次在头对头试验中战胜了PD-1，这次的对手是百济神州（688235.SH）的替雷利珠单抗。4月23日早间，康方生物宣布依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）的注册性III期头对头临床研究（AK112-306/HARMONi-6），经独立数据监察委员会（IDMC）评估...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529502592?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-23 09:38","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2529502592","market":"us","top_or_hot":-1,"title":"康方生物在一项临床三期试验中赢了百济神州的PD-1抗体联合疗法","media":"每日经济新闻","content":"<div>\n<p>康方生物（9926.HK，股价92.3港元，市值828.46亿港元）双抗药物依沃西又一次在头对头试验中战胜了PD-1，这次的对手是百济神州（688235.SH）的替雷利珠单抗。4月23日早间，康方生物宣布依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）的注册性III期头对头临床研究（AK112-306/HARMONi-6），经独立数据监察委员会（IDMC）评估...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物在一项临床三期试验中赢了百济神州的PD-1抗体联合疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物在一项临床三期试验中赢了百济神州的PD-1抗体联合疗法\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-23 09:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>康方生物（9926.HK，股价92.3港元，市值828.46亿港元）双抗药物依沃西又一次在头对头试验中战胜了PD-1，这次的对手是百济神州（688235.SH）的替雷利珠单抗。4月23日早间，康方生物宣布依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）的注册性III期头对头临床研究（AK112-306/HARMONi-6），经独立数据监察委员会（IDMC）评估...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b","article_id":"2529502592","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2529502592","pubTimestamp":1745372280,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"康方生物双抗药物依沃西又一次在头对头试验中战胜了PD-1，这次的对手是百济神州的替雷利珠单抗。在此次头对头试验中，依沃西联合化疗把替雷利珠单抗联合化疗作为对照组。康方生物表示，HARMONi-6临床试验共入组532例受试者，中央型鳞癌占比约为63%，与真实世界患者分布一致。与治疗相关的严重不良反应发生率以及三级及以上出血事件发生率与对照组相似。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4023":"应用软件","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","ONC":"百济神州","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4139":"生物科技","PD":"PagerDuty, Inc."},"translate_title":"Akeso won BeiGene's PD-1 antibody combination therapy in a phase III clinical trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"ONC":1},"content_text":"康方生物（9926.HK，股价92.3港元，市值828.46亿港元）双抗药物依沃西又一次在头对头试验中战胜了PD-1，这次的对手是百济神州（688235.SH）的替雷利珠单抗。4月23日早间，康方生物宣布依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）的注册性III期头对头临床研究（AK112-306/HARMONi-6），经独立数据监察委员会（IDMC）评估的期中分析显示强阳性结果：达到无进展生存期（PFS）的主要研究终点，研究结果具有统计学显著获益和重大临床获益。肺癌根据癌细胞的形态，可初步分为非小细胞肺癌（NSCLC）和小细胞肺癌(SCLC)。其中NSCLC占比约85%，它又能进一步被分为三类，分别是腺癌、鳞癌和大细胞癌，肺鳞癌占所有肺癌病例的25%~30%。《每日经济新闻》记者了解到，大部分驱动基因突变发生在肺腺癌，肺鳞癌驱动基因突变较少，患者的生存预后相对较差。随着免疫治疗药物的上市，sq-NSCLC患者的生存期得到明显改善。恒瑞医药近期披露的一项随机、双盲、多中心、III期临床试验(CameL-sq研究)5年长期随访数据显示，超四分之一的患者生存期突破五年。2024年欧洲肿瘤内科学会（ESMO）年会披露的数据显示，在RATIONALE-307长期随访结果中，接受一线替雷利珠单抗联合化疗治疗患者的4年OS率（总生存率）高达32.2%，即有三分之一患者的生存可达4年甚至更长时间。在此次头对头试验中，依沃西联合化疗把替雷利珠单抗联合化疗作为对照组。康方生物表示，HARMONi-6临床试验共入组532例受试者，中央型鳞癌占比约为63%，与真实世界患者分布一致。研究数据表明，在意向治疗人群(ITT)中，依沃西联合化疗组的患者无进展生存期（PFS）相较对照组，获得了决定性胜出的阳性结果。在安全性方面，依沃西组总体表现良好，未发现新的安全性信号。与治疗相关的严重不良反应发生率以及三级及以上出血事件发生率与对照组相似。记者注意到，去年依沃西在单药头对头临床试验中战胜帕博利珠单抗（K药），此次也是依沃西第2个头对头PD-1疗法取得阳性结果的III期临床研究，来自全国共66家临床研究中心参与了此项研究。封面图片来源：每经记者 孔泽思 摄","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529502592","isCrawlerRequest":true}